760 results on '"Zander T"'
Search Results
2. Endoluminal occlusion devices: technology update
3. Conflicting Worlds: New Dimensions of the American Civil War: The Politics of Antimilitarism in the Civil War Era
4. Combined regression score predicts outcome after neoadjuvant treatment of oesophageal cancer
5. Improved Tissue Processing in Esophageal Adenocarcinoma After Ivor Lewis Esophagectomy Allows Histological Analysis of All Surgically Removed Lymph Nodes with Significant Effects on Nodal UICC Stages
6. Hitzebedingte Übersterblichkeit unter in Nordrhein-Westfalen Krebserkrankten im fortgeschrittenen Stadium
7. Joint interpretation of geophysical field experiments in the danube deep-sea fan, Black Sea
8. 43O A dose-escalation study of TNO155 (TN) in combination with spartalizumab (SPA) or ribociclib (RIB) in adults with advanced solid tumors
9. Home parenteral nutrition (HPN) using individually compounded PN via A 7/8/9-Multi-chamber system versus PN via 2/3-chamber bags in subjects with metastatic or localized solid tumors requiring HPN - The IKF-010 Pekannuss trial
10. Hospital 2090: How Nowadays Technology Could Contribute to the Future of the Hospitals
11. Vorschlag für ein Verfahren zur Teilnahme an intensiv- und notfallmedizinischen Studien bei nichteinwilligungsfähigen Patient*innen (Kölner Modell)
12. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
13. SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY
14. Profit-Center-Analyse der Ösophagektomie: Ökonomische Analyse der transthorakalen Ösophagektomie in Abhängigkeit von postoperativen Komplikationen
15. Hospital 2090: How Nowadays Technology Could Contribute to the Future of the Hospitals
16. P09.12 Hereditary homozygosity and allelic imbalance of HLA as common immune escape mechanisms in esophageal adenocarcinoma
17. Comparison of eight published static finite element models of the intact lumbar spine: Predictive power of models improves when combined together
18. Utilizing Secondary Input from Passive Brain-Computer Interfaces for Enhancing Human-Machine Interaction
19. Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel
20. Lungenkarzinom und rheumatoide Arthritis: Eine interdisziplinäre Herausforderung
21. Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts
22. HEREDITARY HOMOZYGOSITY AND ALLELIC IMBALANCE OF HLA AS COMMON IMMUNE ESCAPE MECHANISMS IN ESOPHAGEAL ADENOCARCINOMA
23. Spotlight on pomalidomide: could less be more?
24. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients
25. Molekular stratifizierte Therapie und patientenrelevante Endpunkte: Ein Widerspruch?
26. Chirurgische Therapie pulmonaler Metastasen von Kopf-Hals-Tumoren
27. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
28. Integrated Genomic Profiling of Endometrial Carcinoma Associates Aggressive Tumors with Indicators of PI3 Kinase Activation
29. 1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
30. Applying a follower load delivers realistic results for simulating standing
31. Realistic loading conditions for upper body bending
32. Monitoring the load on a telemeterised vertebral body replacement for a period of up to 65 months
33. Parameters influencing the outcome after total disc replacement at the lumbosacral junction. Part 1: misalignment of the vertebrae adjacent to a total disc replacement affects the facet joint and facet capsule forces in a probabilistic finite element analysis
34. PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES
35. SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK
36. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
37. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
38. Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus
39. 1521P Addition of durvalumab to CROSS in oesophageal adenocarcinoma is feasible and safe
40. Thyrosinkinaseinhibitoren in der Onkologie
41. Versteifungseinfluss eines transsakralen Fusionssystems: Eine probabilistische Finite-Elemente-Analyse und Sensitivitätsstudie
42. BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination: ID 422
43. A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany: ID 461
44. Clinical and Molecular Characteristics of Non-Small Cell Lung Cancer Patients Harboring PIK3CA Mutations: ID 431
45. MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab: ID 439
46. Retrograde Embolization of the Left Vertebral Artery in a Type II Endoleak After Endovascular Treatment of Aortic Thoracic Rupture: Technical Note
47. Flexible non-fusion scoliosis correction systems reduce intervertebral rotation less than rigid implants and allow growth of the spine: a finite element analysis of different features of orthobiom™
48. Biomechanische Konsequenzen von verschiedenen Positionierungen bewegungserhaltender Bandscheibenimplantate: Eine Finite-Elemente-Studie an der Lendenwirbelsäule
49. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
50. impact on future treatment strategies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.